Tyra Biosciences, Inc. TYRA
Tyra Biosciences, Inc. (Nasdaq: TYRA) is an oncology drug developer. Its lead program, Dabogratinib (oral, formerly TYRA-300), is in Phase 2 for FGFR3-altered urothelial cancers (LG-UTUC, IR NMIBC) and achondroplasia. Its next catalyst on record is Dabogratinib BEACH301: Safety sentinel cohort results incl. 6-month annualized height velocity (March 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Dabogratinib BEACH301 — Safety sentinel cohort results incl. 6-month annualized height velocity (March 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Dabogratinib SURF303 | Low-grade upper tract urothelial carcinoma | small molecule | Phase 2 |
| Dabogratinib SURF302 | Intermediate-risk NMIBC | small molecule | Phase 2 |
| Dabogratinib BEACH301 | Achondroplasia in children | small molecule | Phase 2 |
| TYRA-430 (SURF431) | FGF19+ hepatocellular carcinoma | small molecule | Phase 1 |
| TYRA-200 (SURF201) | FGFR2-driven intrahepatic cholangiocarcinoma | small molecule | Phase 1 |
Recent results and decisions
- Sep 9, 2026positive Initial SURF302 data: 60 mg QD ORR 79% (11/14) with 57% CR at 3 months; 50 mg QD ORR 67% (8/12); favorable safety, no Grade 4/5 TEAEs.
The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA’s planned registrational adjuvant development strategy.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
- Faeth Therapeutics, Inc. FTH
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.